DOCSLIB.ORG

Paulovich Lab Monoclonal Antibodies Available for Immuno-MRM Assays

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Paulovich Lab Monoclonal Antibodies Available for Immuno-MRM Assays TABLE 1: Paulovich Lab Monoclonal Antibodies available for Immuno-MRM Assays. Mab Mab Mab NCI CPTAC Peptide NCI CPTAC UniProt Modification Mab host Assay works in works in works Gene Symbol Target Protein Name FHCRC Antibody ID Antibody Portal Modification Assay Portal ID Reference ID (& link) Site species Species immuno- Western in ID (& link) detected (& link) MRM Blot ELISA Actin; ACTA2 ACTA1 ACTB ACTG1 ACTC1 ACT Q562L2 EB0957-6F5-H1/K1 Non-modified Rabbit Human Yes No TBD ACTG2 ACTN4 Alpha-actinin-4 O43707 MGP10-1A7b Non-modified Mouse Human Yes TBD TBD ADA adenosine deaminase P00813 EB0150D-R1H6-H2/K2 Non-modified Rabbit Human Yes TBD TBD Schoenherr et al, J. Immun. ADAM17 ADAM17 metalloprotease domain 17 P78536 FHC-29-83-17 Non-modified Mouse Human Yes No TBD Meth. (2010) 353: 49-61 AFP Alpha-fetoprotein P02771 CPTAC-23a-48-7 Non-modified Rabbit Human Yes No TBD AKT1 RAC-alpha serine/threonine-protein kinase P31749 FSAI105-12F5 Non-modified Mouse Human Yes Yes TBD AKT1 RAC-alpha serine/threonine-protein kinase P31749 FSAI105-1C11 Non-modified Mouse Human Yes No TBD Phosphorylation & AKT1 RAC-alpha serine/threonine-protein kinase P31749 FSAI106-2E2 pT308 Mouse Human Yes Yes TBD Non-modified AKT1 RAC-alpha serine/threonine-protein kinase P31749 LBR-101-12-7 Phosphorylation pT308 Rabbit Human Yes TBD TBD Phosphorylation & AKT1 RAC-alpha serine/threonine-protein kinase P31749 LBR-101-4-2 pT308 Rabbit Human Yes TBD TBD Non-modified AKT1 RAC-alpha serine/threonine-protein kinase P31749 LBR-102-20-1 Phosphorylation pS473 Rabbit Human Yes TBD TBD Phosphorylation & AKT2 activating transcription factor 2 P31751 FSAI083-1G9 pS473 Mouse Human Yes Yes TBD Non-modified Phosphorylation & AKT2 activating transcription factor 2 P31751 FSAI083-2D10 pS473 Mouse Human Yes Yes TBD Non-modified AKT2 activating transcription factor 2 P31751 FSAI084-17G10 Non-modified Mouse Human Yes No TBD AKT2 activating transcription factor 2 P31751 FSAI084-6H8 Non-modified Mouse Human Yes No TBD AKT2 activating transcription factor 2 P31751 LBR-103-22-6 Phosphorylation pS473 Rabbit Human Yes TBD TBD Phosphorylation & AKT2 activating transcription factor 2 P31751 LBR-103-24-5 pS473 Rabbit Human Yes TBD TBD Non-modified Phosphorylation & AKT3 RAC-gamma serine/threonine-protein kinase Q9Y243 FSAI086-9H8 pS472 Mouse Human Yes Yes TBD Non-modified AKT3 RAC-gamma serine/threonine-protein kinase Q9Y243 FSAI177-3D8 Non-modified Mouse Human Yes TBD TBD AKT3 RAC-gamma serine/threonine-protein kinase Q9Y243 FSAI177-4B11 Non-modified Mouse Human Yes TBD TBD AKT3 RAC-gamma serine/threonine-protein kinase Q9Y243 FSAI177-4D10 Non-modified Mouse Human Yes TBD TBD Phosphorylation & AKT3 RAC-gamma serine/threonine-protein kinase Q9Y243 LBR-104-10-4 pS472 Rabbit Human Yes TBD TBD Non-modified Phosphorylation & AKT3 RAC-gamma serine/threonine-protein kinase Q9Y243 LBR-104-2-5 pS472 Rabbit Human Yes TBD TBD Non-modified AKT3 RAC-gamma serine/threonine-protein kinase Q9Y243 LBR-104-3-7 Phosphorylation pS472 Rabbit Human Yes TBD TBD ALCAM activated leukocyte cell adhesion molecule Q13740 EB0975A-4F9-H3/K2 Non-modified Rabbit Human Yes TBD TBD ALCAM activated leukocyte cell adhesion molecule Q13740 EB0975A-5C8-H2/K1 Non-modified Rabbit Human Yes TBD TBD Schoenherr et al, MCP (2015) ANXA1 Annexin A1 P04083 SAIC-13B-19 H3/L3 CPTC-ANXA1-4 Non-modified Rabbit Human CPTAC-696 Yes No No 14(2):382-98. Schoenherr et al, MCP (2015) ANXA1 Annexin A1 P04083 SAIC-13C-5G10 H3/L2 CPTC-ANXA1-5 Non-modified Rabbit Human CPTAC-697 Yes No No 14(2):382-98. Schoenherr et al, MCP (2015) ANXA4 Annexin A4 P09525 SAIC-14C-10F12 H1/L3 CPTC-ANXA4-1 Non-modified Rabbit Human Yes Yes Yes 14(2):382-98. ARAF Serine/threonine-protein kinase A-Raf P10398 FSAI081-1D12 Non-modified Mouse Human Yes Yes TBD ARAF Serine/threonine-protein kinase A-Raf P10398 FSAI081-2F10 Non-modified Mouse Human Yes No TBD ARAF Serine/threonine-protein kinase A-Raf P10398 FSAI082-5A6 Non-modified Mouse Human Yes Yes TBD Phosphorylation & ARAF Serine/threonine-protein kinase A-Raf P10398 FSAI082-5H4 pS299 Mouse Human Yes Yes TBD Non-modified ARAF Serine/threonine-protein kinase A-Raf P10398 LBR-105-22-7 Phosphorylation pS299 Rabbit Human Yes TBD TBD ARG1 arginase, liver P05089 EB0965E-2C10-H1/K2 Non-modified Rabbit Human Yes TBD TBD ARG2 arginase, type II P78540 EB0122C-1F5-H1/K1 Non-modified Rabbit Human Yes TBD TBD Serine-protein kinase ATM, Ataxia Phosphorylation & ATM Q13315 FHC-114-18-2 pS2996 Rabbit Human Yes No TBD telangiectasia mutated Non-modified Serine-protein kinase ATM, Ataxia ATM Q13315 FHC-114-19-9 Phosphorylation pS2996 Rabbit Human Yes No TBD telangiectasia mutated Serine-protein kinase ATM, Ataxia Phosphorylation & ATM Q13315 FHC-116-38-6 pS367 Rabbit Human Yes No TBD telangiectasia mutated Non-modified Serine-protein kinase ATM, Ataxia ATM Q13315 FHC-116-6-10 Phosphorylation pS367 Rabbit Human Yes No TBD telangiectasia mutated Phosphorylation & ATR Serine/threonine-protein kinase ATR Q13535 FHC-117-1-12 pT1989 Rabbit Human Yes Yes TBD Non-modified ATRIP ATR interacting protein Q8WXE1 FHC-118-3-6 Phosphorylation pS224 Rabbit Human Yes Yes TBD Phosphorylation & ATRIP ATR interacting protein Q8WXE1 FHC-119-33-9 pS518 Rabbit Human Yes Yes TBD Non-modified B2M beta-2-microglobulin P61769 EB0108-3B4-H1/K2 Non-modified Rabbit Human Yes TBD TBD BAX BCL2-associated X protein Q07812 EB0976C-1C12-H2/K2 Non-modified Rabbit Human Yes TBD TBD BCL10 B-cell CLL/lymphoma 10 O95999 EB0152B-6C6-H2/K2 Non-modified Rabbit Human Yes TBD TBD BIRC5 baculoviral IAP repeat-containing 5 (survivin) O15392 MGP5-8C7b Non-modified Mouse Human Yes TBD TBD BIRC5 baculoviral IAP repeat-containing 5 (survivin) O15392 MGP5-8D6b Non-modified Mouse Human Yes TBD TBD v-raf murine sarcoma viral oncogene BRAF P15056 FSAI091-6A5 Non-modified Mouse Human Yes No TBD homolog B1 v-raf murine sarcoma viral oncogene BRAF P15056 FSAI091-6E3 Non-modified Mouse Human Yes Yes TBD homolog B1 v-raf murine sarcoma viral oncogene BRAF P15056 FSAI091-9H5 Non-modified Mouse Human Yes No TBD homolog B1 v-raf murine sarcoma viral oncogene Phosphorylation & BRAF P15056 FSAI092-1G1 pT401 Mouse Human Yes Yes TBD homolog B1 Non-modified v-raf murine sarcoma viral oncogene BRAF P15056 FSAI092-1H9 Non-modified Mouse Human Yes No TBD homolog B1 v-raf murine sarcoma viral oncogene BRAF P15056 FSAI092-4G11 Non-modified Mouse Human Yes Yes TBD homolog B1 v-raf murine sarcoma viral oncogene Phosphorylation & BRAF P15056 LBR-107-1-4 pT401 Rabbit Human Yes TBD TBD homolog B1 Non-modified Phosphorylation & BRCA1 Breast cancer type 1 susceptibility protein P38398 SAIC-116-15-7 pS1524 Rabbit Human Yes Yes TBD Non-modified Phosphorylation & BRCA2 Breast cancer type 2 susceptibility protein P51587 FHC-124-23-5 pS1680 Rabbit Human Yes Yes TBD Non-modified BRCA1 interacting protein C-terminal Phosphorylation & BRIP1/FANCJ Q9BX63 FHC-128-62-2 pS930 Rabbit Human Yes No TBD helicase 1 / Fanconi anemia group J protein Non-modified BRCA1 interacting protein C-terminal Phosphorylation & BRIP1/FANCJ Q9BX63 SAIC-114-114-1 pS1032 Rabbit Human Yes No TBD helicase 1 / Fanconi anemia group J protein Non-modified BRCA1 interacting protein C-terminal BRIP1/FANCJ Q9BX63 SAIC-114-92-9 Phosphorylation pS1032 Rabbit Human Yes No TBD helicase 1 / Fanconi anemia group J protein BTK Bruton agammaglobulinemia tyrosine kinase Q06187 EB0153B-R1G9-H1/K1 Non-modified Rabbit Human Yes TBD TBD BTLA B and T lymphocyte associated Q7Z6A9 FSAI194-12F6 Non-modified Mouse Human Yes TBD TBD BTLA B and T lymphocyte associated Q7Z6A9 FSAI194-2H1 Non-modified Mouse Human Yes TBD TBD BTLA B and T lymphocyte associated Q7Z6A9 FSAI194-6C4 Non-modified Mouse Human Yes TBD TBD C10orf54 chromosome 10 open reading frame 54 Q9H7M9 EB0135B-5D8-H2/K2 Non-modified Rabbit Human Yes TBD TBD C10orf54 chromosome 10 open reading frame 54 Q9H7M9 FSAI170-16G10 Non-modified Mouse Human Yes TBD TBD C17orf70 / Chromosome 17 open reading frame 70 / Phosphorylation & Q0VG06 FHC-130-22-10 pS667 Rabbit Human Yes Yes TBD FAAP100 Fanconi anemia-associated protein of 100 Non-modified C17orf70 / Chromosome 17 open reading frame 70 / Q0VG06 FHC-130-8-4 Phosphorylation pS667 Rabbit Human Yes Yes TBD FAAP100 Fanconi anemia-associated protein of 100 CADM1 cell adhesion molecule 1 Q9BY67 FSAI198R-6D7 Non-modified Mouse Human Yes TBD TBD CADM1 cell adhesion molecule 1 Q9BY67 FSAI198R-7C8-1G11 Non-modified Mouse Human Yes TBD TBD Schoenherr et al, MCP (2015) CALR Calreticulin P27797 SAIC-16D-6B9 H2/L3 CPTC-CALR-1 Non-modified Rabbit Human CPTAC-698 Yes Yes Yes 14(2):382-98. Phosphorylation & CASC5 cancer susceptibility candidate 5 Q8NG31 EB0915-3A2-H1/K1 pS767 Rabbit Human Yes No TBD Non-modified caspase 3, apoptosis-related cysteine CASP3 P42574 EB0929-3A5-H2/K3 Phosphorylation pS26 Specific Human Yes No TBD peptidase CCL5 C-C motif chemokine ligand 5 P13501 FSAI157-18A7 Non-modified Mouse Human Yes TBD TBD CCL5 C-C motif chemokine ligand 5 P13501 FSAI157-2H5 Non-modified Mouse Human Yes TBD TBD CCND1 cyclin D1 P24385 FSAI075-1H1 Non-modified Mouse Human Yes Yes TBD CCND1 cyclin D1 P24385 FSAI075-2C7 Non-modified Mouse Human Yes Yes TBD CCND1 cyclin D1 P24385 FSAI075-2H7 Non-modified Mouse Human Yes No TBD CCND1 cyclin D1 P24385 FSAI075-5C11 Non-modified Mouse Human Yes No TBD CCND1 cyclin D1 P24385 FSAI076-1F8 Non-modified Mouse Human Yes No TBD CCND1 cyclin D1 P24385 FSAI076-1G12 Non-modified Mouse Human Yes No TBD CCND1 cyclin D1 P24385 FSAI076-2E4 Non-modified Mouse Human Yes Yes TBD CCNE1 cyclin E1 P24864 RSAP4-1F4d Non-modified Mouse Yes TBD TBD CD14
Load more

Recommended publications
  • Immuno-Oncology Panel 1
    Immuno-Oncology panel 1 Gene Symbol Target protein name UniProt ID (& link) Modification* (56 analytes) ADA17 ADAM17 metalloprotease domain 17 P78536 *blanks mean the assay detects the ANXA1 Annexin A1 P04083 non-modified peptide sequence ANXA1 Annexin A1 P04083 ARG2 arginase, type II P78540 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 pS2996 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 pS367 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 C10orf54 / VISTA chromosome 10 open reading frame 54 Q9H7M9 CCL5 C-C motif chemokine ligand 5 P13501 CD14 CD14 molecule P08571 CD163 CD163 molecule Q86VB7 CD274 / PDL1 Programmed cell death 1 ligand 1 CD274 Q9NZQ7 CD33 CD33 molecule P20138 CD40/TNR5 tumor necrosis factor receptor superfamily member 5 P25942 CD40/TNR5 tumor necrosis factor receptor superfamily member 5 P25942 CD47 CD47 molecule Q08722 CD70 CD70 antigen P32970 CD74/HG2A CD74 molecule, major histocompatibility complex, class II invariant chain Q8SNA0 CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 P31997 CX3CL1 C-X3-C motif chemokine ligand 1 P78423 CXCL10 C-X-C motif chemokine ligand 10 P02778 CXCL13 chemokine (C-X-C motif) ligand 13 O43927 ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 Q86VV3 FAS/TNR6 Fas (TNF receptor superfamily, member 6) P25445 pY291 FAS/TNR6 Fas (TNF receptor superfamily, member 6) P25445 GAPDH Glyceraldehyde-3-phosphate dehydrogenase P04406 HAVCR2 hepatitis
    [Show full text]
  • Identification of Trichoplein, a Novel Keratin Filament- Binding Protein
    Research Article 1081 Identification of trichoplein, a novel keratin filament- binding protein Miwako Nishizawa1,*, Ichiro Izawa1,*, Akihito Inoko1,*, Yuko Hayashi1, Koh-ichi Nagata1, Tomoya Yokoyama1,2, Jiro Usukura3 and Masaki Inagaki1,‡ 1Division of Biochemistry, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan 2Department of Dermatology, Mie University Faculty of Medicine, 2-174 Edobashi, Tsu 514-8507, Japan 3Department of Anatomy and Cell Biology, Nagoya University School of Medicine, 65 Tsurumai, Showa-ku, Nagoya 466-8550, Japan *These authors contributed equally to this work ‡Author for correspondence (e-mail: [email protected]) Accepted 29 November 2004 Journal of Cell Science 118, 1081-1090 Published by The Company of Biologists 2005 doi:10.1242/jcs.01667 Summary Keratins 8 and 18 (K8/18) are major components of the antibody in a complex with K8/18 and immunostaining intermediate filaments (IFs) of simple epithelia. We report revealed that trichoplein colocalized with K8/18 filaments here the identification of a novel protein termed in HeLa cells. In polarized Caco-2 cells, trichoplein trichoplein. This protein shows a low degree of sequence colocalized not only with K8/18 filaments in the apical similarity to trichohyalin, plectin and myosin heavy chain, region but also with desmoplakin, a constituent of and is a K8/18-binding protein. Among interactions desmosomes. In the absorptive cells of the small intestine, between trichoplein and various IF proteins that we trichoplein colocalized with K8/18 filaments at the apical tested using two-hybrid methods, trichoplein interacted cortical region, and was also concentrated at desmosomes.
    [Show full text]
  • Proteomic Expression Profile in Human Temporomandibular Joint
    diagnostics Article Proteomic Expression Profile in Human Temporomandibular Joint Dysfunction Andrea Duarte Doetzer 1,*, Roberto Hirochi Herai 1 , Marília Afonso Rabelo Buzalaf 2 and Paula Cristina Trevilatto 1 1 Graduate Program in Health Sciences, School of Medicine, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, Brazil; [email protected] (R.H.H.); [email protected] (P.C.T.) 2 Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru 17012-901, Brazil; [email protected] * Correspondence: [email protected]; Tel.: +55-41-991-864-747 Abstract: Temporomandibular joint dysfunction (TMD) is a multifactorial condition that impairs human’s health and quality of life. Its etiology is still a challenge due to its complex development and the great number of different conditions it comprises. One of the most common forms of TMD is anterior disc displacement without reduction (DDWoR) and other TMDs with distinct origins are condylar hyperplasia (CH) and mandibular dislocation (MD). Thus, the aim of this study is to identify the protein expression profile of synovial fluid and the temporomandibular joint disc of patients diagnosed with DDWoR, CH and MD. Synovial fluid and a fraction of the temporomandibular joint disc were collected from nine patients diagnosed with DDWoR (n = 3), CH (n = 4) and MD (n = 2). Samples were subjected to label-free nLC-MS/MS for proteomic data extraction, and then bioinformatics analysis were conducted for protein identification and functional annotation. The three Citation: Doetzer, A.D.; Herai, R.H.; TMD conditions showed different protein expression profiles, and novel proteins were identified Buzalaf, M.A.R.; Trevilatto, P.C.
    [Show full text]
  • Pan-Cancer Analysis Connects Tumor Matrisome to Immune Response
    www.nature.com/npjprecisiononcology ARTICLE OPEN Pan-cancer analysis connects tumor matrisome to immune response Su Bin Lim 1,2, Melvin Lee Kiang Chua 3,4,5, Joe Poh Sheng Yeong6,7, Swee Jin Tan8, Wan-Teck Lim7,9,10 and Chwee Teck Lim 1,2,11,12 Recent sequencing efforts unveil genomic landscapes of tumor microenvironment. A key compartment in this niche is the extracellular matrix (ECM) and its related components – matrisome. Yet, little is known about the extent to which matrisome pattern is conserved in progressive tumors across diverse cancer types. Using integrative genomic approaches, we conducted multi- platform assessment of a measure of deregulated matrisome associated with tumor progression, termed as tumor matrisome index (TMI), in over 30,000 patient-derived samples. Combined quantitative analyses of genomics and proteomics reveal that TMI is closely associated with mutational load, tumor pathology, and predicts survival across different malignancies. Interestingly, we observed an enrichment of specific tumor-infiltrating immune cell populations, along with signatures predictive of resistance to immune checkpoint blockade immunotherapy, and clinically targetable immune checkpoints in TMIhigh tumors. B7-H3 emerged as a particularly promising target for anti-tumor immunity in these tumors. Here, we show that matrisomal abnormalities could represent a potential clinically useful biomarker for prognostication and prediction of immunotherapy response. npj Precision Oncology (2019) 3:15 ; https://doi.org/10.1038/s41698-019-0087-0 INTRODUCTION Here we hypothesized that this specific pattern of deregulated The extracellular matrix (ECM) is a complex multi-spatial mesh- matrisome could be a common determinant of tumor aggression work of macromolecules with structural, biochemical and irrespective of tumor origin.
    [Show full text]
  • Chemical Agent and Antibodies B-Raf Inhibitor RAF265
    Supplemental Materials and Methods: Chemical agent and antibodies B-Raf inhibitor RAF265 [5-(2-(5-(trifluromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-trifluoromethyl)phenyl-1-methyl-1H-benzp{D, }imidazol-2- amine] was kindly provided by Novartis Pharma AG and dissolved in solvent ethanol:propylene glycol:2.5% tween-80 (percentage 6:23:71) for oral delivery to mice by gavage. Antibodies to phospho-ERK1/2 Thr202/Tyr204(4370), phosphoMEK1/2(2338 and 9121)), phospho-cyclin D1(3300), cyclin D1 (2978), PLK1 (4513) BIM (2933), BAX (2772), BCL2 (2876) were from Cell Signaling Technology. Additional antibodies for phospho-ERK1,2 detection for western blot were from Promega (V803A), and Santa Cruz (E-Y, SC7383). Total ERK antibody for western blot analysis was K-23 from Santa Cruz (SC-94). Ki67 antibody (ab833) was from ABCAM, Mcl1 antibody (559027) was from BD Biosciences, Factor VIII antibody was from Dako (A082), CD31 antibody was from Dianova, (DIA310), and Cot antibody was from Santa Cruz Biotechnology (sc-373677). For the cyclin D1 second antibody staining was with an Alexa Fluor 568 donkey anti-rabbit IgG (Invitrogen, A10042) (1:200 dilution). The pMEK1 fluorescence was developed using the Alexa Fluor 488 chicken anti-rabbit IgG second antibody (1:200 dilution).TUNEL staining kits were from Promega (G2350). Mouse Implant Studies: Biopsy tissues were delivered to research laboratory in ice-cold Dulbecco's Modified Eagle Medium (DMEM) buffer solution. As the tissue mass available from each biopsy was limited, we first passaged the biopsy tissue in Balb/c nu/Foxn1 athymic nude mice (6-8 weeks of age and weighing 22-25g, purchased from Harlan Sprague Dawley, USA) to increase the volume of tumor for further implantation.
    [Show full text]
  • WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: David [US/US]; 13539 N . 95th Way, Scottsdale, AZ C12Q 1/68 (2006.01) 85260 (US). (21) International Application Number: (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N . PCT/US20 12/0425 19 Macarthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 June 2012 (14.06.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/497,895 16 June 201 1 (16.06.201 1) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/499,138 20 June 201 1 (20.06.201 1) US OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 61/501,680 27 June 201 1 (27.06.201 1) u s SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/506,019 8 July 201 1(08.07.201 1) u s TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Genome-Wide Association Study of Susceptibility to Idiopathic
    Edinburgh Research Explorer Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis Citation for published version: Allen, RJ, Guillen-Guio, B, Oldham, JM, Ma, S-F, Dressen, A, Paynton, ML, Kraven, LM, Obeidat, M, Li, X, Ng, M, Braybrooke, R, Molina-Molina, M, Hobbs, BD, Putman, RK, Sakornsakolpat, P, Booth, HL, Fahy, WA, Hart, SP, Hill, MR, Hirani, N, Hubbard, RB, McAnulty, RJ, Millar, AB, Navaratnam, V, Oballa, E, Parfrey, H, Saini, G, Whyte, MKB, Zhang, Y, Kaminski, N, Adegunsoye, A, Strek, ME, Neighbors, M, Sheng, XR, Gudmundsson, G, Gudnason, V, Hatabu, H, Lederer, DJ, Manichaikul, A, Newell, JD, O'Connor, GT, Ortega, VE, Xu, H, Fingerlin, TE, Bossé, Y, Hao, K, Joubert, P, Nickle, DC, Sin, DD, Timens, W, Furniss, D, Morris, AP, Zondervan, K, Hall, IP, Sayers, I, Tobin, MD, Maher, TM, Cho, MH, Hunninghake, GM, Schwartz, DA, Yaspan, BL, Molyneaux, PL, Flores, C, Noth, I, Jenkins, RG & Wain, LV 2019, 'Genome- Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis', American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201905-1017OC Digital Object Identifier (DOI): 10.1164/rccm.201905-1017OC Link: Link to publication record in Edinburgh Research Explorer Document Version: Peer reviewed version Published In: American Journal of Respiratory and Critical Care Medicine General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation.
    [Show full text]
  • Pflugers Final
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Serveur académique lausannois A comprehensive analysis of gene expression profiles in distal parts of the mouse renal tubule. Sylvain Pradervand2, Annie Mercier Zuber1, Gabriel Centeno1, Olivier Bonny1,3,4 and Dmitri Firsov1,4 1 - Department of Pharmacology and Toxicology, University of Lausanne, 1005 Lausanne, Switzerland 2 - DNA Array Facility, University of Lausanne, 1015 Lausanne, Switzerland 3 - Service of Nephrology, Lausanne University Hospital, 1005 Lausanne, Switzerland 4 – these two authors have equally contributed to the study to whom correspondence should be addressed: Dmitri FIRSOV Department of Pharmacology and Toxicology, University of Lausanne, 27 rue du Bugnon, 1005 Lausanne, Switzerland Phone: ++ 41-216925406 Fax: ++ 41-216925355 e-mail: [email protected] and Olivier BONNY Department of Pharmacology and Toxicology, University of Lausanne, 27 rue du Bugnon, 1005 Lausanne, Switzerland Phone: ++ 41-216925417 Fax: ++ 41-216925355 e-mail: [email protected] 1 Abstract The distal parts of the renal tubule play a critical role in maintaining homeostasis of extracellular fluids. In this review, we present an in-depth analysis of microarray-based gene expression profiles available for microdissected mouse distal nephron segments, i.e., the distal convoluted tubule (DCT) and the connecting tubule (CNT), and for the cortical portion of the collecting duct (CCD) (Zuber et al., 2009). Classification of expressed transcripts in 14 major functional gene categories demonstrated that all principal proteins involved in maintaining of salt and water balance are represented by highly abundant transcripts. However, a significant number of transcripts belonging, for instance, to categories of G protein-coupled receptors (GPCR) or serine-threonine kinases exhibit high expression levels but remain unassigned to a specific renal function.
    [Show full text]
  • Chromosomal Microarray Analysis in Turkish Patients with Unexplained Developmental Delay and Intellectual Developmental Disorders
    177 Arch Neuropsychitry 2020;57:177−191 RESEARCH ARTICLE https://doi.org/10.29399/npa.24890 Chromosomal Microarray Analysis in Turkish Patients with Unexplained Developmental Delay and Intellectual Developmental Disorders Hakan GÜRKAN1 , Emine İkbal ATLI1 , Engin ATLI1 , Leyla BOZATLI2 , Mengühan ARAZ ALTAY2 , Sinem YALÇINTEPE1 , Yasemin ÖZEN1 , Damla EKER1 , Çisem AKURUT1 , Selma DEMİR1 , Işık GÖRKER2 1Faculty of Medicine, Department of Medical Genetics, Edirne, Trakya University, Edirne, Turkey 2Faculty of Medicine, Department of Child and Adolescent Psychiatry, Trakya University, Edirne, Turkey ABSTRACT Introduction: Aneuploids, copy number variations (CNVs), and single in 39 (39/123=31.7%) patients. Twelve CNV variant of unknown nucleotide variants in specific genes are the main genetic causes of significance (VUS) (9.75%) patients and 7 CNV benign (5.69%) patients developmental delay (DD) and intellectual disability disorder (IDD). were reported. In 6 patients, one or more pathogenic CNVs were These genetic changes can be detected using chromosome analysis, determined. Therefore, the diagnostic efficiency of CMA was found to chromosomal microarray (CMA), and next-generation DNA sequencing be 31.7% (39/123). techniques. Therefore; In this study, we aimed to investigate the Conclusion: Today, genetic analysis is still not part of the routine in the importance of CMA in determining the genomic etiology of unexplained evaluation of IDD patients who present to psychiatry clinics. A genetic DD and IDD in 123 patients. diagnosis from CMA can eliminate genetic question marks and thus Method: For 123 patients, chromosome analysis, DNA fragment analysis alter the clinical management of patients. Approximately one-third and microarray were performed. Conventional G-band karyotype of the positive CMA findings are clinically intervenable.
    [Show full text]
  • Genome-Wide DNA Methylation in Chronic Myeloid Leukaemia
    Genome-wide DNA Methylation in Chronic Myeloid Leukaemia Alexandra Bazeos Imperial College London Department of Medicine Centre for Haematology Thesis submitted in fulfillment of the requirements for the degree of Doctor of Philosophy of Imperial College London 2015 1 Abstract Epigenetic alterations occur frequently in leukaemia and might account for differences in clinical phenotype and response to treatment. Despite the consistent presence of the BCR-ABL1 fusion gene in Philadelphia-positive chronic myeloid leukaemia (CML), the clinical course of patients treated with tyrosine kinase inhibitors (TKI) is heterogeneous. This might be due to differing DNA methylation profiles between patients. Therefore, a validated, epigenome-wide survey in CML CD34+ progenitor cells was performed in newly diagnosed chronic phase patients using array-based DNA methylation and gene expression profiling. In practice, the CML DNA methylation signature was remarkably homogeneous; it differed from CD34+ cells of normal persons and did not correlate with an individual patient’s response to TKI therapy. Using a meta-analysis tool it was possible to demonstrate that this signature was highly enriched for developmentally dynamic regions of the human methylome and represents a combination of CML-unique, myeloid leukemia- specific and pan-cancer sub-signatures. The CML profile involved aberrantly methylated genes in signaling pathways already implicated in CML leukaemogenesis, including TGF-beta, Wnt, Jak-STAT and MAPK. Furthermore, a core set of differentially methylated promoters were identified that likely have a role in modulating gene expression levels. In conclusion, the findings are consistent with the notion that CML starts with the acquisition of a BCR-ABL1 fusion gene by a haematopoietic stem cell, which then either causes or cooperates with a series of DNA methylation changes that are specific for CML.
    [Show full text]
  • Triangulating Molecular Evidence to Prioritise Candidate Causal Genes at Established Atopic Dermatitis Loci
    medRxiv preprint doi: https://doi.org/10.1101/2020.11.30.20240838; this version posted November 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Triangulating molecular evidence to prioritise candidate causal genes at established atopic dermatitis loci Maria K Sobczyk1, Tom G Richardson1, Verena Zuber2,3, Josine L Min1, eQTLGen Consortium4, BIOS Consortium5, GoDMC, Tom R Gaunt1, Lavinia Paternoster1* 1) MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, UK 2) Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK 3) MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK 4) Members of the eQTLGen Consortium are listed in: Supplementary_Consortium_members.docx 5) Members of the BIOS Consortium are listed in: Supplementary_Consortium_members.docx Abstract Background: Genome-wide association studies for atopic dermatitis (AD, eczema) have identified 25 reproducible loci associated in populations of European descent. We attempt to prioritise candidate causal genes at these loci using a multifaceted bioinformatic approach and extensive molecular resources compiled into a novel pipeline: ADGAPP (Atopic Dermatitis GWAS Annotation & Prioritisation Pipeline). Methods: We identified a comprehensive list of 103 accessible
    [Show full text]
  • The Human Gene Connectome As a Map of Short Cuts for Morbid Allele Discovery
    The human gene connectome as a map of short cuts for morbid allele discovery Yuval Itana,1, Shen-Ying Zhanga,b, Guillaume Vogta,b, Avinash Abhyankara, Melina Hermana, Patrick Nitschkec, Dror Friedd, Lluis Quintana-Murcie, Laurent Abela,b, and Jean-Laurent Casanovaa,b,f aSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065; bLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U980, Necker Medical School, 75015 Paris, France; cPlateforme Bioinformatique, Université Paris Descartes, 75116 Paris, France; dDepartment of Computer Science, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel; eUnit of Human Evolutionary Genetics, Centre National de la Recherche Scientifique, Unité de Recherche Associée 3012, Institut Pasteur, F-75015 Paris, France; and fPediatric Immunology-Hematology Unit, Necker Hospital for Sick Children, 75015 Paris, France Edited* by Bruce Beutler, University of Texas Southwestern Medical Center, Dallas, TX, and approved February 15, 2013 (received for review October 19, 2012) High-throughput genomic data reveal thousands of gene variants to detect a single mutated gene, with the other polymorphic genes per patient, and it is often difficult to determine which of these being of less interest. This goes some way to explaining why, variants underlies disease in a given individual. However, at the despite the abundance of NGS data, the discovery of disease- population level, there may be some degree of phenotypic homo- causing alleles from such data remains somewhat limited. geneity, with alterations of specific physiological pathways under- We developed the human gene connectome (HGC) to over- come this problem.
    [Show full text]